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Abstract:
Little is known about the voltage-gated sodium channels (NaVs) that control neurotransmission in the parasympathetic nervous system. We evaluated the expression of the α subunits of each of the nine NaVs in human, guinea pig, and mouse airway parasympathetic ganglia. We combined this information with a pharmacological analysis of selective NaV blockers on parasympathetic contractions of isolated airway smooth muscle. As would be expected from previous studies, tetrodotoxin potently blocked the parasympathetic responses in the airways of each species. Gene expression analysis showed that that NaV 1.7 was virtually the only tetrodotoxin-sensitive NaV1 gene expressed in guinea pig and human airway parasympathetic ganglia, where mouse ganglia expressed NaV 1.1, 1.3, and 1.7. Using selective pharmacological blockers supported the gene expression results showing that blocking NaV 1.7 alone can abolish the responses in guinea pig and human bronchi, but not in mouse airways. To block the responses in mouse airways requires that NaV 1.7 along with NaV1.1 and/or NaV 1.3 is blocked. These results may suggest novel indications for NaV1.7 blocking drugs where there is an overactive parasympathetic drive such as in asthma. The data also raise the potential concern of anti-parasympathetic side effects for systemic NaV 1.7 blockers.
Introduction
The pore forming α subunits of voltage-gated sodium channels comprise nine distinct subtypes referred to as NaV1.1 -1.9. With respect to the peripheral nervous system they have been extensively investigated in sensory nerves, but much less so in autonomic nerves; and virtually not all in the parasympathetic nervous system. The parasympathetic nervous system controls the function of visceral organs. In the respiratory tract, parasympathetic nerves regulate secretions and provide the dominant control over airway smooth muscle tone and airway caliber. Dysregulation of this system can contribute to airway inflammatory diseases like asthma and COPD (Undem and Potenzieri, 2012) .
Other than the fact that they are generally blocked by tetrodotoxin (TTX), little is known about the neuronal voltage-gated sodium channels (NaV1s) involved in parasympathetic neurotransmission in visceral organs. We have addressed this question here by focusing on the postganglionic parasympathetic nerves controlling airway caliber. TTX potently blocks NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6, and NaV1.7. Among these all but NaV1.4 are expressed by peripheral neurons. Which of these channels are responsible for the TTX-sensitive neuronal cholinergic airway contractions is unknown.
We evaluated the functionality of these channels in airway cholinergic responses using selective NaV1 blocking drugs along with an evaluation of NaV1 gene expression in isolated bronchial associated parasympathetic ganglia in guinea pigs, mice, and humans. The data support the conclusion that airway parasympathetic cholinergic neurotransmission is entirely dependent on NaV1.7 in humans and guinea pigs, but not mice. This information is significant because NaV 1.7 is associated with channelopathies that can lead to a gain or loss of function (Waxman, 2013) . In addition, selective NaV 1.7 blockers are presently being developed aimed at JPET 238469 6 30 min. This capsaicin desenstization treatment prevents subsequent tachykinergic responses to EFS, leaving a neuronal response that is entirely cholinergic in nature (Undem et al., 1990) .
The nerves in the tissue were stimulated using electrical field stimulation. Rectangular pulses were delivered to the tissue via the platinum wire electrodes from the Grass S48 stimulator after first being processed by a constant current Med-Lab Stimul-Splitter (Med-Lab Instruments, Fort Collin CO, USA). The square pulses were of 0.1 msec duration with an amplitude of 12V. The impulses were delivered at 8Hz every 1000 seconds. This resulted in rapid and short-lived atropine-sensitive cholinergic contractions. After stable responses were obtained ~5 minutes, the NaV blocker was added until the reduction in response amplitude reached a steady-state at which time a 10-fold larger dose concentrations was added. From data obtained a cumulative concentration response curve was obtained. At the end of the experiment the tissue was maximally contracted with 100 µM carbamylcholine; the EFS contractions were normalized to this maximum response.
The NaV blockers did not inhibit the contractions to the exogenously applied cholinergic agonist carbamylcholine (100 µM); the contractions averaged 3.6 ± 0.7 g, 5.4 ± 3 g and 4.3 ± 0.9 g, and 5.7 ± 1.2 g in vehicle (n=9), TTX (1µM, n= 6), compound 801 (1 µM, n=8), and compound 13 (10 µM, n=7) treated tissues, respectively (P>0.1 ANOVA). In two experiments we evaluated the concentration-response curve of carbamycholine-induced contractions in vehicle, TTX, compound 801, and compound 13 treated tissues and found them to be nearly superimposable (EC5O values averaged 48 nM, 32 nM, 28 nM, and 49 nM, respectively).
Mouse Trachea
Mouse tracheal rings, two per animal were prepared exactly as previously described (Weigand LA, 2009 ). Indomethacin (3 µM) and propranolol (1 µM) was included in the Kreb's bicarbonate buffer. The field stimulation protocol was the same as described above for guinea pig bronchi This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on January 30, 2017 as DOI: 10.1124 at ASPET Journals on January 31, 2017 jpet.aspetjournals.org Downloaded from except there was a 5 min interval between two consecutive 8 Hz stimulations (in preliminary studies we noted that without such an interval there was a gradual run down of the cholinergic responses over time).
Human Bronchi
Lungs were obtained from human organ donors through the International Institute for the Advancement of Medicine program (Exton, PA, USA). The tissue is immediately placed in chilled (Lactated Ringers solution) and shipped overnight arriving in our laboratory 12-24 h later.
Once received the lungs were placed in 4 L of chilled oxygenated Kreb's bicarbonate buffer solution (see above). Central bronchi (3mm-5mm inner diameter) are dissected free, trimmed of extraneous tissue and prepared for EFS induced isometric study as described for the guinea pig bronchi and in more detail here (Ellis and Undem, 1992) . Intron-spanning primers specific for each guinea pig, human, and mouse, Na V α subunit were designed based on Pubmed sequences with aid of UCSC Genome Browser using Primer3 (v.0.4.0) program (tables 1-3) (Rozen and Skaletsky, 2000) . The selectivity of each primer was evaluated by aligning all Na V subunits with the primer using ClustalW. Positive control RNA was selected based on established Na V subunit expression pattern: whole brain RNA for Na V 1.1, 1.2, 1.3 and 1.6, skeletal muscle RNA for Na V 1.4, heart muscle RNA for Na V 1.5 and DRG or vagal sensory ganglia RNA for Na V 1.7, 1.8 and 1.9. The guinea pig and mouse RNA was isolated by using RNAeasy mini kit (Qiagen). Human RNA was purchased from Clontech.
Analysis of NaV1 subunits expression in parasympathetic ganglion neurons

Electrophysiology
Human Nav1,1, hNav1.2, hNav1.3, hNav1.6, and hNav1.7 stably expressedin HEK cells were obtained from Millipore, and cultured according to manufactures specifications. Mouse Nav1.7, rat Nav1.7 and gpNav1.7-HEK cell lineswere generated at Lilly Laboratories. The media 10mM. Working dilutions were also done using DMSO and the final concentration was tested at a 0.1% DMSO concentration. A steady-state inactivation (SSI) curve is run at a holding potential of -130mV using a 10 second pre-pulse ranging from -130mV to -30mV in 10mV steps followed by a test pulse to -10mV for 10ms at 0.06Hz intervals. The data is then fit to a Boltzman
Sigmoidal to calculate the V 0.5 using Prism and the following formula:
where Y= Current measured at the test pulse, X= Pre-pulse potential.
The SSI curve was repeated every 2 minutes until peak current baselines are stable. The holding potential is then changed to a potential near the calculated V b. Compound 13 selectivity was assessed at Essen Bioscience using human Nav1.1, Nav1.2, hNav1.4, hNav1.5, hNav1.6, and hNav1.7 transfected in HEK cells and Ion Works Barracuda as electrophysiology platform using PPC (Population Patch Clamp) mode. Compound potency was assessed by using functional selectivity protocols consisting in the application of different trains of depolarizations that cycle channels through states that are most representative of pathology for hNav 1.7 and physiology for the rest.Voltage protocols follow the same time scheduled, being applied once in the absence of compound, then in the presence of compound, 5 minutes after addition, and then five more times every one minute.
The external recording solution comprised (in mM): 137 NaCl, 4 KCl, 10 HEPES, 1 MgCl2, 1.8
CaCl2 and pH7.3 with NaOH. The internal solution comprised (in mM): 90 K-gluconate, 40
CsCl, 10 NaCl, 3.2 EGTA, 5 HEPES, 3.2 MgCl2 and pH 7.3 with KOH. All buffer constituents were obtained from Sigma-Aldrich. Electrical access was achieved using amphotericin (120 µg ml -1 ) in the internal solution to obtain the perforated-patch clamp configuration.
Compounds were solubilized in DMSO containing 6% pluronic F127 (Sigma) as 10 mM stock solutions. A 11 point 1:3 cross-plate dilution was carried out in DMSO (6% pluronic), diluted 1/300 in external solution and the added to assay plate using dual addition mode from mid position without mixing to reduce nonspecific binding and improve compound exposure.
Peak inward currents were determined from the first and last depolarizing pulses. % Inhibition values were calculated according to the following equation, using peak currents obtained in the 
Results
In the patch-clamp analysis of various NaV1 currents, TTX inhibits NaV 1.1, 1.2, 1.3, 1.6, and 1.7 with similar potency with IC50 values in the 1-10 nM range. ICA-121431, by contrast potently blocks NaV 1.1, 1.2 and 1.3, but has little effect on 1.6 or 1.7. We noted, for example, that the guinea pig NaV1.7 current was inhibited less than 20% even at 10 µM ICA-121431.
Compound 801 and Compound 13 are arylsulfonamides closely related to other selective NaV1.7 blockers (Alexandrou et al., 2016) . We found Compound 801 to be a potent NaV1.7
blocker, being 5-10 fold more potent at this channel than NaV 1.2 and NaV 1.6. Compound 801 was equally potent against human and guinea pig NaV1.7. Compound 13 was selective for blocking NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, and was found to be more potent at human vs guinea pig NaV1.7 (these data are summarized in table 4).
Guinea Pig Bronchi
TTX, Compound 801, and Compound 13 each effectively blocked the neuronally evoked cholinergic contractions of the guinea pig bronchi with IC50s of 8.4, 56, and 480 nM, respectively. In contrast, ICA121431 at concentrations that would be expected to fully block NaV1.1, 1.2 and 1.3 was virtually devoid of an inhibitory effect on the cholinergic contractions.
These data are illustrated in Fig. 1 . As expected, PF-01247324, a drug that selectively blocks the TTX-resistant NaV 1.8 channels, had no effect on the cholinergic contractions (34 ±3% vs 35±3% in the absence and presence of 1 µM of the drug, respectively; n=6, P>0.1) (Payne et al., 2015) .
NaV1 gene expression was detected in bronchial ganglia (n=11), but not in the juxtaposed nonneuronal tissue. NaV1.7 was the only TTX-sensitive channel mRNA expressed in most guinea pig airway-associated parasympathetic ganglia. NaV1.7 was expressed in 10/11 isolated ganglia. The only other TTX-sensitive channel expressed was NaV 1.3, and this was expressed in only 2/11 ganglia. Interestingly, NaV1.9 was also expressed in 8/11 ganglia. These data are shown in Fig 1. Inasmuch as NaV1.9 is a TTX-resistant channel, these data support the hypothesis based on our functional studies that NaV1.7 provides the functional control over action potential discharge in postganglionic parasympathetic nerves in the guinea pig airways.
Mouse Trachea TTX potently (IC50 21nM) blocked neuronally evoked cholinergic contractions of the mouse trachea. In contrast to guinea pig airways, none of the selective NaV1 blockers when studied alone inhibited the cholinergic responses. However, in the presence of NaV1.1, 1.2, 1.3
blockade with ICA-121431 (10 µM), either Compound 13 or Compound 801 was able to abolish the contractions in a concentration-dependent fashion. Thus, to block parasympathetic responses in the mouse airway both NaV1.7 and NaV1.1, 1.2 and/or NaV1.3 had to also be blocked. These data are illustrated in Fig. 2 .
We evaluated NaV1 gene expression in 5 ganglia isolated from mouse airways. Consistent with the functional studies, The NaV1 expression was more extensive then in guinea pig ganglia.
With respect to TTX-sensitive channels NaV1.1, NaV1.3, NaV1.6, and NaV1.7 was expressed by neurons in 100%, 80%, 40% and 60% of the ganglia, respectively. With respect to TTXresistant channels, NaV1.9 was expressed in 3/5 ganglia (Fig.2) .
Human Bronchi
The large differences in the NaV1 regulating airways parasympathetic responses between guinea pig and mice begs the question as to which laboratory animal is the more translatable to the human condition. Like the guinea pig and mouse, the neuronally-evoked cholinergic contractions were potently and effectively blocked by TTX. Blocking NaV1.1, 1.2 and 1.3 with ICA-121431 had no effect on the cholinergic responses whereas either Compound 801 or
Compound 13 mimicked the TTX response (Fig. 3) . Consistent with our potency predictions obtained with patch clamp electrophysiological studies of human vs guinea pig NaV1.7 in heterologous systems (table 1), Compound 13 was more potent in blocking the parasympathetic contractions in human bronchi than guinea pig bronchi (Fig 1 and Fig. 3 ).
We evaluated the NaV1 gene expression in 5 ganglia isolated from the bronchi of 3 human donors. NaV 1.7 mRNA was expressed in every parasympathetic ganglia, whereas other TTXsensitive NaV1s were largely unexpressed with the exception of NaV 1.3 which was found in only 1 of 5 ganglia (Fig. 3 ).
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Discussion
The functional and mRNA expression data support the hypothesis that neurotransmission in parasympathetic postganglionic neurons innervating smooth muscle in human and guinea pig airways is under the control of NaV1.7. On the other hand in the mouse, the most commonly employed laboratory animal for investigations into both NaV1 biology and respiratory physiology, the parasympathetic neurons were under redundant control of NaV1.7 and 1.1 and/or 1.3. One must therefore be cautious when drawing NaV1 related conclusions about human autonomic nerves from physiological studies carried out exclusively in mice.
NaV1.9 was expressed along with NaV 1.7, especially in guinea pig parasympathetic neurons.
That TTX and the selective NaV1.7 blockers could abolish the parasympathetic response indicated that NaV 1.9 is not sufficient for driving action potential discharge and acetylcholine release from the terminals. This is as would be expected based on its biophysical properties, but it may play a role in regulating the electrical excitability of the neurons.
The potency of NaV blockers in blockers in isolated tissues is generally less than that seen in patch-clamp electrophysiological studies. There are several potential reasons for this. First, the concentration of the inhibitor in the tissue bath solution may not reflect that concentration in the biophase of the nerve endings. To minimize this issue we incubated the blocking drug for a period sufficient such that the inhibitory effect reached a steady-state. Secondly, the potency of NaV blockers including aryl sulfonamide blockers such as compounds 801 and 13, can be dramatically influenced by the biophysical state of the channel (Alexandrou et al., 2016) . The clamp conditions, but remains unknown in channels inserted within nerve membranes in tissues. Finally, the beta subunit composition may potentially influence the pharmacology of the NaV blockers (Wilson et al., 2015) , and this may differ in channels expressed in heterologous system vs channels in the parasympathetic nerves within tissues. In the present study it is noteworthy that the potency of the selective NaV1.7 blockers relative to TTX was similar in the tissue assay and patch-clamp analysis.
Alterations in both the sensory and parasympathetic nervous systems likely contribute to airway pathologies such as asthma and COPD (reviewed in (Undem and Potenzieri, 2012; Mazzone and Undem, 2016) ). That NaV1.7 is the dominant controller of neurotransmission in human and guinea pig airway parasympathetic neurons provides for a strategy of limiting parasympathetic tone in the respiratory tract via selective NaV1.7 blockade. Topically administered antimuscarinic drugs are presently used to decrease cholinergic tone in the airways of those suffering from asthma or COPD. Blocking NaV 1.7 is an orthogonal approach to diminish cholinergic contractions and may have the added benefit of not only blocking the release of acetylcholine but also other parasympathetic transmitters including for example VIP and nitric oxide that provide pro-mucus secretory activities (Baker et al., 1985; Wine, 2007) . The VIP/nitric oxide containing postganglionic nerves in the guinea pig airways, however, are derived from parasympathetic neurons distinct from the cholinergic neurons(Canning and Undem, 1993) , and therefore may reveal distinct NaV1 channel expression. The airway parasympathetic ganglia are mainly associated with larger central airways. The neurons within these ganglia then project postganglionic nerves to the smooth muscle of bronchi and bronchioles (Undem and Potenzieri, 2012) . Another speculative benefit therefore of topically applied (inhaled) NaV blocking drugs over muscarinic receptor antagonists is that even central deposition of an NaV blocker my lead to bronchodilation of more peripheral bronchi and bronchioles. Finally, we have recently reported that blocking NaV1.7 can inhibit action potential conduction along sensory C-fibers in the respiratory tract leading to inhibition of undesirable sensations such as dyspnea and urge to cough; an effect that anti-muscarinic drugs would not share (Muroi et al., 2011; Muroi et al., 2013) . It should be kept in mind that the present study focused on airways from healthy laboratory animals and donors that did not have asthma or COPD; both the expression and function of NaV channels may potentially be altered in the diseased state (Chahine and O'Leary, 2014) .
There has been intensive efforts in developing selective NaV1.7 blockers for the treatment of pain (Dib-Hajj et al., 2013) . As far as we know this is the first study on the NaV1 expression and function in parasympathetic neurons. If our observations in the respiratory tract hold true for other visceral organs it may suggest new indications for NaV1.7 blockers. The findings may also explain potential anti-parasympathetic side-effects for systemically acting NaV1.7 blockers.
Individuals with loss of function and gain of mutations in NaV1.7 have been identified (Dib-Hajj et al., 2005; Goldberg et al., 2007) . These people suffer from a congenital insensitivity to pain or erythomelalgia, respectively. Loss of function mutation also lead to a decreased sensitivity of smell (Weiss et al., 2011) . Based on the present data, one might predict that those with loss of function mutations may experience less reflex bronchial contractions and secretions, and perhaps less airway reactive disease like asthma, but this hypothesis has yet to be addressed. a All values are for human NaV1 channels except for the guinea pig (GP) NaV 1.7 values.
The values for TTX were obtained from (Catterall et al., 2005) except for the the NaV 1.7s which were obtained here as described in methods.
b The values for compound 801 were obtained as described in methods 
